This global guide resolves EGRIFTA WR to its fda-approved us medicine with a withdrawn eu application first, then connects that identity to 42 country guides across five regions. Each country card opens the official product and seller or supply records that must be checked before any claim about approval, availability, legality, or a vendor can be supported.
Start with the question you actually need answered. Each route keeps the EGRIFTA WR identity, official trial record, destination status, and comparison dataset separate.
Skip the full atlas when you already know the destination. The result keeps the compound identity, national product record, and seller or supply record separate.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
FDA-approved US medicine with a withdrawn EU application
Official product and seller records attached
US research-market identity with a separate FDA-licensed medicine record
EGRIFTA WR is an FDA-approved US tesamorelin prescription product with an exact application, presentation, indication, label, and regulated supply chain. The European Egrifta marketing-authorisation application was withdrawn in 2012. Neither record authenticates research vials, compounded preparations, imported packages, or seller claims, and neither establishes current authorization or supply in another jurisdiction.
Primary identity source: Current EGRIFTA WR prescribing information / National Library of Medicine, DailyMed ↗These answers define the evidence boundary. They do not provide medical or legal advice, a seller recommendation, or a country-wide availability claim.
No single worldwide answer is supportable. EGRIFTA WR begins here with a US FDA medicine identity, but the authorized brand, presentation, indication, prescription route, market status, and seller authority can differ by country. Verify the exact destination records below.
No. A page using the name EGRIFTA WR, a local currency, domestic delivery language, or a familiar vial image is only a lead. It does not prove the exact product identity, local authorization, current supply status, pharmacy or establishment license, import route, or seller authority.
Resolve EGRIFTA WR through its primary identity record first. Then open the destination country's product database and its separate seller, pharmacy, establishment, or supply record. Compare offers only when the category, legal seller identity, exact presentation, delivery market, price, and source date all match.
The same sequence works worldwide while the responsible authority, terminology, records, and available supply routes change by destination.
Use the primary identity record for EGRIFTA WR, including aliases and the correct research, clinical-pipeline, or medicine evidence lane.
Open the country guide and match the exact product, presentation, current status, authorization holder, and supply route in the national record.
Resolve the legal seller, pharmacy, clinic, establishment, or importer in the applicable official register before comparing a claim, price, or delivery route.
Each regional summary preserves the compound’s evidence lane and links to every maintained national verification route in that part of the world.
EGRIFTA WR in Europe begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR in Latin America begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR in North America begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR in Middle East and Africa begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR in Europe begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR commence ici par une référence de médicament de la FDA américaine. Cela ne prouve pas le même produit, la même présentation, l’autorisation, le statut de prescription ou la disponibilité actuelle en France. Consultez les registres locaux exacts ci-dessous.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United Kingdom. Verify the exact local records below.
EGRIFTA WR beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Deutschland. Prüfe die genauen lokalen Register unten.
EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en España. Verifica los registros locales exactos que aparecen abajo.
EGRIFTA WR parte qui da un riferimento di farmaco della FDA statunitense. Questo non dimostra stesso prodotto, presentazione, approvazione, stato di prescrizione o disponibilità attuale in Italia. Controlla i registri locali esatti qui sotto.
EGRIFTA WR begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in Nederland. Controleer de exacte lokale registers hieronder.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Switzerland. Verify the exact local records below.
EGRIFTA WR zaczyna się tutaj od dokumentu leku amerykańskiej FDA. Nie dowodzi to tego samego produktu, postaci, dopuszczenia, statusu recepty ani bieżącej dostępności w Polsce. Sprawdź dokładne rejestry krajowe poniżej.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Ireland. Verify the exact local records below.
EGRIFTA WR começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, autorização, estatuto de prescrição ou disponibilidade atual em Portugal. Consulte os registos locais exatos abaixo.
EGRIFTA WR börjar här med en läkemedelsreferens från amerikanska FDA. Det bevisar inte samma produkt, presentation, godkännande, receptstatus eller aktuell tillgänglighet i Sverige. Kontrollera de exakta nationella registren nedan.
EGRIFTA WR kimliği burada bir ABD FDA ilaç kaydıyla başlar, ancak bu Türkiye için aynı ürünün, farmasötik şeklin, dozun, ruhsatın, reçete durumunun veya güncel tedarikin bulunduğunu kanıtlamaz. Aşağıdaki resmi kayıtlarla tam ürün ve satıcı kimliğini, güncel durumu ve iddia edilen yolu doğrulayın.
EGRIFTA WR beginnt hier mit einer Arzneimittelreferenz der US-FDA. Das belegt weder dasselbe Produkt noch Darreichungsform, Zulassung, Verschreibungsstatus oder aktuelle Verfügbarkeit in Österreich. Prüfe die genauen lokalen Register unten.
EGRIFTA WR begint hier met een geneesmiddelreferentie van de Amerikaanse FDA. Dat bewijst niet hetzelfde product, dezelfde presentatie, toelating, receptstatus of actuele beschikbaarheid in België. Controleer de exacte lokale registers hieronder.
EGRIFTA WR begynder her med en amerikansk FDA-lægemiddelidentitet, men det dokumenterer ikke samme produkt, form, styrke, godkendelse, receptstatus eller aktuelle forsyning i Danmark. Brug de officielle registre nedenfor til at kontrollere det nøjagtige lokale produkt, sælgeren, status og den påståede rute.
EGRIFTA WR alkaa tässä Yhdysvaltain FDA:n lääkeidentiteetistä, mutta se ei todista samaa tuotetta, lääkemuotoa, vahvuutta, hyväksyntää, reseptistatusta tai nykyistä toimitusta kohteessa Suomi. Tarkista täsmällinen paikallinen tuote, myyjä, tila ja väitetty reitti alla olevista virallisista rekistereistä.
EGRIFTA WR in Latin America begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en México. Verifica los registros locales exactos que aparecen abajo.
EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Argentina. Verifica los registros locales exactos que aparecen abajo.
EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Colombia. Verifica los registros locales exactos que aparecen abajo.
EGRIFTA WR empieza aquí con una referencia de medicamento de la FDA estadounidense. Eso no demuestra el mismo producto, presentación, aprobación, estado de prescripción ni disponibilidad actual en Chile. Verifica los registros locales exactos que aparecen abajo.
EGRIFTA WR começa aqui com uma referência de medicamento da FDA dos EUA. Isso não comprova o mesmo produto, apresentação, aprovação, status de prescrição ou disponibilidade atual no Brasil. Consulte os registros locais exatos abaixo.
EGRIFTA WR in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR在此从美国 FDA 药品身份记录开始，但这不能证明同一品牌、剂型、规格、适应症、处方状态或供应路径在中国同样获批或可得。应使用下方官方记录核对目的地的具体产品和卖方，并确认当前状态，而不是依据名称、包装图片或国外批准作出推断。
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Australia. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in New Zealand. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in India. Verify the exact local records below.
EGRIFTA WRはここでは米国FDAの医薬品記録から同一性を確認しますが、日本で同じ製品、剤形、規格、承認、処方区分、供給状況が存在することを証明しません。下記の公的記録で目的地の具体的な製品と販売主体を確認してください。
EGRIFTA WR은 여기서 미국 FDA 의약품 기록으로 신원을 시작하지만, 대한민국에서 같은 제품, 제형, 함량, 허가, 처방 상태 또는 현재 공급이 존재한다는 뜻은 아닙니다. 아래 공식 기록을 이용해 목적지의 구체적인 제품과 판매 주체를 확인하세요.
EGRIFTA WR เริ่มจากบันทึกยาของ FDA สหรัฐฯ แต่ไม่ได้พิสูจน์ว่าผลิตภัณฑ์ รูปแบบ ความแรง การอนุมัติ สถานะใบสั่งยา หรือการจัดหาในประเทศไทยเหมือนกัน ให้ตรวจผลิตภัณฑ์และผู้ขายที่เฉพาะเจาะจงในประเทศปลายทางจากบันทึกทางการด้านล่าง
EGRIFTA WR dimulai dari identitas obat dalam catatan FDA Amerika Serikat, tetapi hal itu tidak membuktikan produk, bentuk, kekuatan, persetujuan, status resep, atau pasokan yang sama di Indonesia. Gunakan catatan resmi di bawah untuk memeriksa produk dan penjual spesifik di negara tujuan.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Singapore. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the Philippines. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Malaysia. Verify the exact local records below.
EGRIFTA WR在此從美國 FDA 藥品紀錄確認身分，但這不能證明台灣有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄查證目的地的特定產品、許可證、機構和提供者，不能只依名稱或外國核准推論。
EGRIFTA WR在此從美國 FDA 藥物紀錄確認身分，但這不能證明香港有相同產品、劑型、含量、適應症、處方狀態或目前供應。請用下方官方紀錄核實指定產品、註冊編號、持牌銷售商和現行狀態，不能只依名稱或外國批准推論。
EGRIFTA WR bắt đầu ở đây bằng hồ sơ thuốc của FDA Hoa Kỳ, nhưng điều đó không chứng minh có cùng sản phẩm, dạng bào chế, hàm lượng, giấy phép, tình trạng kê đơn hay nguồn cung hiện tại tại Việt Nam. Hãy dùng các hồ sơ bên dưới để xác minh chính xác sản phẩm, người bán, tình trạng và đường cung ứng tại điểm đến.
EGRIFTA WR in North America begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in the United States. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
EGRIFTA WR in Middle East and Africa begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
تبدأ هوية EGRIFTA WR هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في الإمارات العربية المتحدة. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.
تبدأ هوية EGRIFTA WR هنا من سجل دواء لدى إدارة الغذاء والدواء الأمريكية، لكن ذلك لا يثبت أن المنتج أو الشكل أو التركيز أو الموافقة أو حالة الوصفة أو التوفر الحالي هي نفسها في المملكة العربية السعودية. تحقق من المنتج المحلي المحدد والمنشأة والبائع ومسار التوريد من خلال السجلات الرسمية أدناه.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Nigeria. Verify the exact local records below.
EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
The compound identity source is linked above. Every country card links its national product and seller or supply records, then opens a localized guide with the full verification boundary.
Open the EGRIFTA WR identity record →Compare EGRIFTA WR across 50 US states →Compare EGRIFTA WR across 10 Canadian provinces →Download all 1722 compound-country rows →Download all 2050 compound-state rows →Download all 410 compound-province rows →Audit the regional access dataset →Review the complete source registry →Read the publication standard →